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ScienceDirectEndo-lysosomal pathways are essential in maintaining protein
homeostasis in the cell. Numerous genes in the endo-
lysosomal pathways have been found to associate with
neurodegenerative diseases, including Alzheimer’s disease
(AD), Parkinson’s disease (PD), and frontotemporal dementia
(FTD). Mutations of these genes lead to dysfunction in multiple
steps of the endo-lysosomal network: autophagy, endocytic
trafficking and lysosomal degradation, resulting in
accumulation of pathogenic proteins. Although the exact
pathogenic mechanism varies for different disease-associated
genes, dysfunction of the endo-lysosomal pathways
represents a converging mechanism shared by these diseases.
Therefore, strategies that correct or compensate for endo-
lysosomal dysfunction may be promising therapeutic
approaches to treat neurodegenerative diseases.
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Introduction
Neurodegenerative diseases are often characterized by
intracellular protein inclusions or extracellular protein
aggregates. Failure of proper trafficking and degradation
of these proteins could underlie neuronal and network
dysfunction in these diseases. The lysosome system is
one of the major cellular mechanisms for protein degra-
dation, especially in long-lived, post-mitotic cells, such as
neurons. Lysosomes serve as the hub for proteostasis
(Figure 1). Protein substrates of extracellular andCurrent Opinion in Neurobiology 2018, 48:52–58 intracellular origin are delivered to lysosome through
endocytic trafficking and autophagic pathways, respec-
tively. Complex cross talk between these trafficking
systems ensures proper sorting and degradation of the
substrates. Dysfunction of various steps in this network
can lead to insufficient clearance of pathogenic proteins,
impaired membrane trafficking and signaling, and dam-
age to the cell. Numerous studies in human genetics and
model organisms support critical roles of lysosomal dys-
function in neurodegeneration. In this review, we focus
on the role of endo-lysosomal dysfunction in three of
the most common and devastating neurodegenerative
diseases: Alzheimer’s disease (AD), Parkinson’s disease
(PD) and frontotemporal dementia (FTD).
Alzheimer’s disease
AD, the most common dementia, is characterized by
extracellular amyloid-b (Ab) plaques and neurofibrillary
tangles (NFT), consisting of hyperphosphorylated tau.
The endo-lysosomal and autophagic networks are critical
to maintain the homeostasis of Ab and tau. Dysfunctions
of this network are common in AD and result in abnormal
lysosomal enzymatic activity and accumulation of autop-
hagosomes and autolysosomes in the dystrophic neurites
in AD brains [1]. More importantly, both familial muta-
tions and polymorphisms associated with late onset spo-
radic AD are linked with autophagic and endo-lysosomal
dysfunctions (Figure 1).
Mutations in presenilins 1 and 2 (PS1, 2), the proteases of
the g-secretase complex, cause rare early-onset familial
cases of AD (FAD). Most FAD-linked mutations of PS1
and PS2 increase the production of Ab42, supporting
amyloid hypothesis. However, PS1 also appears to regu-
late autophagic-lysosomal function, resulting in altera-
tions in the hydrolysis of amyloid precursor protein (APP).
PS1 mutations or knockout (KO) cause v-ATPase V0a1
subunit deficiency and disruption of lysosomal acidifica-
tion, leading to abnormal Ca2+ homeostasis and defective
autophagy [2]. PS2 localizes to late endosomes/lyso-
somes and produces a distinct intracellular pool of Ab
[3]. FAD mutations in PS2 increase Ab production, and
some PS1 mutations phenocopy the late endosome/lyso-
some location of PS2 [3].
Recent genome-wide association studies (GWAS) further
highlighted the importance of autophagic-lysosomal
function in AD pathogenesis [4]. The risk factors includewww.sciencedirect.com
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Overview of the endo-lysosomal system involved in pathogenesis of AD, PD and FTD. Lysosomes receive inputs from both the endocytic pathway
and autophagic pathway, delivering protein substrates from extracellular environment and intracellular compartment, respectively. Proteins
undergoing clathrin-mediated endocytosis are enclosed by early endosomes, where they are sorted to trans-Golgi network (TGN) by retromers, or
to the late endosomes/multivesicular body (MVB), which fuses with lysosome for degradation. Cytosolic protein substrates are engulfed by
double-membrane phagophore, which becomes an autophagosome, and delivered to lysosome. Autophagy is also responsible for degradation of
damaged organelles, such as mitochondria (mitophagy). TFEB, a master regulator of the biogenesis of lysosomes and autophagosomes, is
translocated from the cytosol to nucleus in response to mTORC inactivation (e.g. nutrient starvation), leading to increased transcription of
autophagic and lysosomal genes. Vesicles in the endo-lysosomal system could fuse with plasma membrane and release the undegraded
substrates, leading to secretion of the pathogenic proteins (dash arrow). Causative genes and risk factors in AD, PD and FTD that are involved in
the endo-lysosomal dysfunction are indicated.genes related to autophagic initiation and early autopha-
gosome formation, such as phosphatidylinositol-binding
clathrin assembly protein (PICALM), a key component of
clathrin-mediated endocytosis machinery. Altered
PICALM protein levels were observed in late-onset
AD brains and are closely related to tau pathology
[5,6]. mRNA and protein levels of beclin 1 (BECN1), a
key component of autophagy biogenesis, are reduced in
AD brains [7]. BECN1 was also reduced in microglia from
AD patients, which are associated with reduced retromer
trafficking, suggesting deficits in receptor-mediated Ab
phagocytosis [8]. Besides Ab degradation, autophagy
might also be involved secretion of Ab to the extracellular
space and may contribute to plaque formation [9].www.sciencedirect.com AD-associated genetic variations also contribute to abnor-
mal sorting and trafficking in endo-lysosomal networks.
Deletion of bridging integrator 1 (BIN1), a genetic risk
factor of late-onset AD, increases cellular b-secretase
(BACE1) levels by impairing its lysosomal degradation,
leading to increased Ab production [10]. Rab11, a com-
ponent that regulates membrane trafficking, controls
BACE1 recycling to the plasma membrane and is a
genetic factor involved in late-onset AD [11]. Endosomal
trafficking is largely controlled by phosphatidylinositol-3-
phosphate (PI3P), and deficiency of PI3P (caused by
VPS34 reduction) reduces sorting of APP to intraluminal
vehicles and contributes to AD [12]. The optimal pH of
early endosome for BACE1 makes the endosome theCurrent Opinion in Neurobiology 2018, 48:52–58
54 Neurobiology of diseasepredominant location for beta cleavage of APP, whereas
APP delivered to lysosome is rapidly degraded. Deletion
of components of endosomal sorting complexes required
for transport (ESCRT) inhibited delivery of APP to
lysosome and increased Ab accumulation [13]. On the
other hand, enhancing lysosome biogenesis through tar-
geting transcription factor EB (TFEB), a master regulator
of lysosome biogenesis and a substrate of mTOR,
reduced steady state APP levels and amyloid deposits
in APP/PS1 mice [14], and ameliorated neurofibrillary
tangle pathology in rTg4510 tauopathy model [15].
AD brains have altered lysosomal protein levels and enzy-
matic activity, some of which are directly involved in Ab
degradation. Increased lysosomal activities of b-hexosa-
minidase and b-galactosidase were found in the cortex of
the TgCRND8 mouse model as the disease progresses and
were associated with synapses loss [16]. The protein level
and enzymatic activity of lysosomal enzyme glucocereb-
rosidase (GBA) are significantly reduced in sporadic AD
[17]. Overexpression of GBA promotes Ab42 degradation
and protects against Ab42 induced toxicity [17]. Cathepsin
B (CatB), a lysosomal cysteine protease, degrades Ab42
[18–20]. CatB activity has also been linked to the clearance
of tau species [21]. A progressive, age-dependent reduc-
tion of CatB activity was observed in an APP/PS1 AD
mouse model [22]. Loss of CatB in culture cell results in
accumulation of BACE1, bCTF and Ab, together with
cholesterol and other lysosomal proteins [23]. Genetic
deletion of the endogenous inhibitors of lysosomal cyste-
ine proteases leads to cathepsin-dependent amelioration
of amyloid pathologies [19,24,25]. Moreover, increasing
CatB expression through AAV reduces Ab and rescues AD-
associated memory deficits [26]. Interestingly, exercise
elevates CatB levels in monkeys and humans, and those
levels correlated with improvements in the type of mem-
ory encoding lost in AD [27].
Parkinson’s disease
PD is the second most common late-onset neurodegen-
erative disease and is characterized by an accumulation of
a-synuclein and mitochondrial dysfunction. Increasing
evidence from genetics and model systems indicates that
intracellular trafficking and endo-lysosomal/autophagic
dysfunction is the primary cause in PD [28].
PTEN-induced putative kinase 1 (PINK1) and parkin,
two key components for mitophagy, are associated with
autosomal recessive parkinsonism, providing compelling
evidence that autophagy dysfunction has a key role in PD
[29]. a-Synuclein is not only a substrate of autophagy, but
also a regulator of autophagic network. Overexpressing
a-synuclein causes mislocalization of the autophagosome
formation protein Atg9 and impairs macroautophagy [30].
Mutations in the leucine-rich repeat kinase 2 (LRRK2) are
one of the most common causes of autosomal dominant
PD. Although its exact effect is controversial, LRRK2Current Opinion in Neurobiology 2018, 48:52–58 regulates autophagy. This regulation involves vesicle sort-
ing, lysosome positioning and clustering, and interaction
with Rab proteins, including Rab7, Rab5 and Rab32 [31–
33]. PD-causing mutations in LRRK2 (G2019S and
R1441C) inhibit autophagy and accelerate age-related
autophagy dysfunction, whereas wildtype LRRK2
improved autophagy [34]. Mutations of late endosomal/
lysosomal ATPase ATP13A2 (Park9) are associated with
early-onset of PD [35,36]. ATP13A2 regulates autophagy
by regulating another PD-associated gene synaptotagmin
11 (SYT11) [37]. In addition, altered autophagosome
trafficking could lead to increased secretion of a-synuclein
[38], suggesting a role of the autophagic-lysosomal
system in the unconventional secretion of their protein
substrates.
Lysosomal dysfunction has a prominent role in PD path-
ogenesis (Figure 1). a-Synuclein oligomeric intermedi-
ates are degraded by lysosomes [39]. Several lysosomal
genes were identified as genetic risk factors for PD.
Heterozygous mutations of glucocerebrosidase (GBA)
are one of the most common risk factors for PD. About
10% PD patients carry GBA mutations (PD-GBA).
Reduced GBA activity and impaired autophagic flux,
together with accumulation of a-synuclein in lysosome,
were found in neurons derived from induced pluripotent
stem cells (iPSCs) carrying GBA mutations [40]. Consis-
tently, activation of GBA by a small-molecule modulator
or chaperone reduced a-synuclein levels and restored
lysosomal function in iPSC-derived dopaminergic neurons,
implicating that lysosomal enzyme is a viable target for PD
treatment [41,42]. Human transmembrane protein 175
(TMEM175) gene, encoding a K+ channel located in late
endosomes and lysosomes, was identified as a risk factor by
a PD GWAS meta-analysis [43]. Deficiency of TMEM175
resulted in unstable lysosomal pH, decreased GBA activity
and mitochondrial respiration, impaired autophagosome
clearance and increased phosphorylated a-synuclein
aggregates [44]. Deficiency or loss-of-function mutations
of ATP13A2 result in impaired lysosomal acidification and
degradation capacity, leading to accumulation of a-synu-
clein [45]. However, in an ATP13A2 KO mouse model,
lysosomal and protein trafficking deficiency occurred with-
out any a-synuclein abnormalities, suggesting the pres-
ence of a-synuclein-independent neurotoxicity induced
by endo-lysosomal dysfunction in PD [46].
Dysfunction of endo-lysosomal sorting and trafficking
also contributes to PD pathogenesis. a-Synuclein disrupts
hydrolase trafficking and reduces lysosomal function,
which can be rescued by expression of small GTPase
Rab1a [47]. VPS35 is a component of retromer complex
involved in endosome-lysosome sorting and trafficking.
An autosomal-dominant PD-causing mutation in VPS35
implicated retromer dysfunction in familial PD [48].
Moreover, cells expressing mutated VPS35 (D620N)
show Atg9 mislocalization and impaired macroautophagywww.sciencedirect.com
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other trafficking machinery.
Frontotemporal dementia
FTD is the second most common cause of dementia in
people under 65 years old. Pathologically, major FTD
variants include inclusions of microtubule-associated pro-
tein tau or the TAR DNA-binding protein (TDP)-43,
named FTLD-tau and FTLD-TDP, accordingly. FTD
mutations of tau lead to increased tau accumulation and
aggregation, where autophagic dysfunction plays an
important role. Blocking autophagy increases tau accu-
mulation [50], while enhancing autophagy lowers the
levels of total and phosphorylated tau [51–53]. Phosphor-
ylated tau linked to Ab42 treatment was also found to be
reduced through enhancement of the autophagy-lyso-
somal pathway [54], from a study that implicates lyso-
somal cross talk with the proteasomal protein clearance
system. Besides tau degradation, it is speculated that
autophagy could be involved in release of tau
through a process called unconventional secretion [55],
although exact mechanism is unknown. TDP-43 inclu-
sions are found in about 45–60% of all FTLD cases.
Stimulation of the autophagy pathway enhances the
TDP-43 clearance, and therefore, the survival of mouse
neurons [56]. Thus, autophagy might play a role in
the degradation of aggregated TDP-43.
Up to 50% of FTD cases are genetic, associated with
causative mutations (e.g. C9orf72, GRN) or risk factors (e.
g. TMEM106B), many of which are genes involved in
endo-lysosomal system. Other rare mutations in FTLD-
causing genes, namely valosin-containing protein (VCP)/
p97, charged multivesicular body protein 2B (CHMP2B),
optineurin (OPTN), TANK binding protein 1 (TBK1),
SQSTM1/p62 and ubiquilin 2 (UBQLN2) affect proteins
that are directly involved in protein degradation, espe-
cially in autophagy-lysosome pathways.
C-Terminal truncations in CHMP2B are a rare genetic
cause of FTD, identified in two European families.
CHMP2B is part of ESCRT-III, a multiprotein complex
involved in the endo-lysosome pathway. Patients with
this mutation show ubiquitin and p62 inclusions in the
dentate gyrus, and enlarged vacuoles in cortical neurons
resembling late endosomes [57], pointing to defects in the
endo-lysosomal pathway. CHMP2B dysfunction is also
linked to impaired autophagosome formation and accu-
mulation of protein aggregates [58]. Mice expressing
CHMP2BIntron5 developed large and dense autofluores-
cent aggregates in several brain regions (90% of microglia
and over 50% of neurons) by 18 months of age [59].
Likewise, FTD patients have a significant amount of
autofluorescent deposits in brain [59]. Moreover, iPSC-
derived neurons from patients with CHMP2B mutation
have enlarged endosomes that can be reverted in thewww.sciencedirect.com CRISPR/Cas9-edited isogenic control [60], demonstrat-
ing a causative role of CHMP2B mutation in FTD.
C9orf72 mutations with GGGGCC repeat expansion in
the non-coding region account for more than 20% of
familial FTD. Pathogenic mechanisms of these muta-
tions include a toxic gain of function and lysosomal
dysfunction. C9orf72 localizes to the lysosomes under
starvation conditions in HEK cells [61], implicating its
involvement in autophagy. C9orf72 KO leads to lysosomes
enlargement and redistribution in Hela cell [61], and
accumulation of vesicles in mouse bone marrow-derived
macrophages and microglia [62]. The mechanism under-
lying the lysosomal dysfunction in C9orf72 deficiency has
been connected to TFEB, the master regulator of lyso-
some biogenesis. Under starvation conditions, C9orf72 KO
MEFs show increased TFEB expression in response to
mTOR inactivation [63]. Likewise, brain homogenates
from C9orf72 KO mice had increased numbers of TFEB
and the lysosomal markers, Lamp1 and Lamp2 [63].
Fibroblasts from patients with C9orf72 mutation had fewer
endosomes and a different expression pattern of mannose
6-phosphate receptor (M6PR), hinting at disruption of
endo-lysosomal pathway [64].
Another major cause of familial FTLD-TDP is mutations
on progranulin (GRN, PGRN), which lead to nonsense-
mediated decay and PGRN halpoinsufficiency. Interest-
ingly, a homozygous GRN loss-of-function mutation
causes adult-onset neuronal ceroid lipofuscinosis, but
results in FTLD-TDP when in a heterozygous state.
Further supporting critical role of PGRN in lysosomal
function, PGRN knockout mice exhibit striking lipofus-
cinosis and intracellular PGRN is highly enriched in the
lysosomes. Expressed by microglia and neurons, PGRN is
involved in the lysosomal and inflammatory pathways in
the brain. PRGN KO leads to upregulation of lysosomal
and innate immunity genes, increased complement pro-
duction, and enhanced synaptic pruning in microglia
[65]. While lysosome biogenesis and microglial activa-
tion were evident, lysosomal degradation was compro-
mised in glia and neurons [66]. A recent study showed
that FTD patients with PGRN haploinsufficiency exhibit
lysosomal dysfunction and a mild form of NCL [67].
Lysosomal protease is impaired in FTD patient-derived
fibroblasts [67], and retinal scanning revealed preclini-
cal retinal lipofuscinosis in heterozygous GRN mutation
carriers [67]. These findings provide evidence that
lysosomal dysfunction induced by PGRN haploinsuffi-
ciency could underlie the pathogenesis of FTLD-TDP
[67].
Conclusion
Accumulating genetic evidence from GWAS has pointed
to a critical role for the endo-lysosomal network in
neurodegenerative diseases. Dysfunction of these genes
and their pathways converges on impaired lysosomalCurrent Opinion in Neurobiology 2018, 48:52–58
56 Neurobiology of diseasedegradation, leading to accumulation of pathogenic pro-
teins. Besides, accumulation of intermediate vesicles con-
taining undegraded proteins might lead to increased secre-
tion and propagation of the pathogenic proteins, although
the molecular mechanism remains elusive. Therapeuti-
cally, those disease-associated genes and their interacting
components in the endo-lysosomal pathway could be
targets for interventions. Several studies have shown ther-
apeutic potentials from various aspects in the endo-lyso-
somal system, through increasing autophagic/lysosomal
biogenesis (e.g. TFEB), promoting vesicular trafficking
(e.g. Rab11, Chmp2B), and enhancing lysosomal degrada-
tion (e.g. GBA, CatB). On the other hand, deficits in
components of endo-lysosomal and autophagic networks
can serve as biomarkers for disease diagnosis. As we gain a
more complete understanding of the molecular mecha-
nisms underlying these pathways, more therapeutic targets
and strategies will be revealed for treating these disorders.
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